News
EMA has recommended refusal of marketing authorisation for Omblastys for the treatment of neurobastoma.
The European Medicines Agency has recommended the refusal of the marketing authorisation for Omblastys, a medicine intended for the treatment of neuroblastoma, a rare cancer that forms from immature nerve cells. The Agency issued its opinion on 15 December 2022.
Y-mAbs Therapeutics A/S, the company that applied for authorisation, may ask for re-examination of the opinion within 15 days of receiving the opinion.
Condition: Neuroblastoma
Type: drug